Zc(=o)oy, Wherein Z Is An Acyclic Radical Bonded To The C=o By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/546)
Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.
Abstract: Ophthalmic compositions that comprise 0.1 ppm to 2 ppm of poly(hexamethylene biguanide); and 0.005 wt. % to 0.3 wt. % of a PEG-glycerol ester of general formula I wherein R1 is a C3-C8alkyl and R2 is H or a C1-C4alkyl; and x+y+z has an average value from 8 to 30. The invention is also directed to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.
Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
Type:
Grant
Filed:
January 22, 2010
Date of Patent:
August 6, 2013
Assignee:
UCB Pharma GmbH
Inventors:
Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
Abstract: A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs.
Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.
Abstract: The present invention relates to benzyloxyanilide derivatives having the following structural formula: The compounds of the present invention are useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.
Type:
Grant
Filed:
May 29, 2012
Date of Patent:
July 23, 2013
Assignee:
Valeant Pharmaceuticals International
Inventors:
Jim Zhen Wu, Jean-Michel Vernier, Huanming Chen, Jianlan Song
Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
Type:
Grant
Filed:
June 6, 2011
Date of Patent:
July 23, 2013
Assignee:
AmDerma Pharmaceuticals, LLC
Inventors:
Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
Abstract: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of chemical analogues of the said sulfur-containing compound and the preparation of these compounds.
Abstract: The present invention relates to stable pharmaceutical compositions comprising fesoterodine or salts thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine which does not contain sugar alcohols. The invention also relates to processes for making such compositions and use thereof in treating patients with urinary incontinence.
Abstract: The present invention relates to a method for the prophylactic and/or therapeutic treatment of glucocorticoid induced osteoporosis comprising maintaining or restoring AP-1 activity or AP-1-mediated effects, for example by LIF treatment. The method may additionally comprise a method for the treatment of a medical condition associated with inflammation comprising inhibition of NF-KB activity, for example by glucocorticoid (GC) treatment. The present invention therefore also relates to a method for the treatment and/or prevention of glucocorticoid induced osteoporosis comprising the administration of an effective amount of LIF to a subject, preferably in combination with GC treatment.
Type:
Application
Filed:
December 7, 2012
Publication date:
July 4, 2013
Applicant:
Fritz-Lipmann-Institut E. V. Leibniz-Institut Fuer Altersforschung
Inventor:
Fritz-Lipmann-Institut E. V. Leibniz-Institut Fuer
Abstract: The invention relates to polyethylene glycol esters and blends of the polyethylene glycol esters with polyethylene glycol ethers, together with in particular cosmetic and/or dermatological preparations containing them, methods for the production thereof and use thereof.
Type:
Grant
Filed:
April 9, 2008
Date of Patent:
July 2, 2013
Assignee:
Symrise AG
Inventors:
Gerhard Schmaus, Sabine Lange, Rolf Ohrmann, Martina Issleib
Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
Type:
Grant
Filed:
September 23, 2009
Date of Patent:
June 25, 2013
Assignee:
Cogenia SRL
Inventors:
Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
Abstract: Environmentally friendly, low whitening compositions are described. The compositions have aromatic alcohols and esters with a melting point from about 20° C. to about 40° C. The compositions are substantially free of silicones and suitable to impart excellent sensory characteristics in the absence of whitening and when topically applied to the skin of a consumer.
Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Abstract: The present invention relates to a novel use of compounds having the general formula (I): CH3(—CH?CH)n—R??(I) where n=from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O—CO—R?, CO—OR?, CO—O(-), where R? is chosen from among H, the alkyl from C1 to C22, each compound of general formula (I) being used as such or in a mixture, as an active principle in a pharmaceutical or cosmetic composition to improve the human epidermal cell repair activity by means of the production of keratin mediated by the cytokeratins cK-19.
Type:
Application
Filed:
February 6, 2013
Publication date:
June 13, 2013
Applicant:
GIULIANI S.P.A.
Inventors:
Giammaria GIULIANI, Anna BENEDUSI, Sergio BARONI
Abstract: Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.
Type:
Application
Filed:
June 22, 2011
Publication date:
June 13, 2013
Applicants:
NORTHEAST OHIO MEDICAL UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
Abstract: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.
Abstract: The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5? reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.
Abstract: The invention is a novel series of compounds represented by general formula, its analogs, tautomeric forms, stereoisomers, pharmaceutically acceptable salts and polymorphs wherein said compound described is a group of antisense molecules possessing immediate global cellular penetration due to their molecular structure and lipophilicity. The molecules are combinations of ethyl and methyl pyruvates. They induce riboswitch activity and reduce target RNA and nucleic acids such as HbA1c. They reduce inflammation and enhance energy production. These features improve therapeutic outcomes of diabetes, neuropathy and cellular aging.
Type:
Application
Filed:
August 9, 2012
Publication date:
June 6, 2013
Inventors:
John James Fitzgerald, JR., Ranya Ludwig Alexander, Anthony Joseph Meduri
Abstract: An object of the present invention is to provide a novel technology for preventing crystal precipitation of p-menthane-3,8-diol, and stable products utilizing this technology. Provided is a p-menthane-3,8-diol isomer mixture, wherein the mass ratio of cis isomers:trans isomers in terms of the relative configuration at Positions 3 and 4 is 55:45 to 45:55. Also provided are stable products and the like containing the p-menthane-3,8-diol isomer mixture.
Abstract: The disclosure pertains to methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a statin in combination with an effective amount of a dipyridamole and/or a compound that has dipyridamole activity.
Type:
Application
Filed:
January 13, 2011
Publication date:
May 23, 2013
Applicant:
UNIVERSITY HEALTH NETWORK
Inventors:
Linda Penn, Aaron Schimmer, Aleksandra Pandyra
Abstract: An application method of 1-monopropionine compound and its isoform 3-monopropionine being used as preserving agents in animal feeds, corns, grains, and other food materials. The monopropionine compounds are obtained by esterification reaction of propionic acid and glycerol. The product is a translucent viscous liquid composition comprising monopropionine compounds and other components, such as free acid, or certain salt forms of propionate. The generated composition can be further distilled in glycerol. The final product can take a liquid form or a powder form. 1-monopropionine compound and its isoform 3-monopropionine function as preserving agent at a low effective dosage of about 0.05 to 1% (by weight), and preferably 0.1 to 0.3% (by weight). A preferable application condition of this method is to preserve animal feeds and corns under a low (about 2% to 12%) moisture condition.
Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.
Type:
Application
Filed:
April 28, 2011
Publication date:
May 23, 2013
Applicant:
Gachon University of Industry-Academic Cooperation Foundation
Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.
Type:
Application
Filed:
January 6, 2011
Publication date:
May 23, 2013
Applicants:
THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCH
Inventors:
Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
Abstract: Disclosed are high-loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
May 18, 2009
Date of Patent:
May 21, 2013
Assignee:
Pharmalyte Solutions, LLC
Inventors:
Stephen F. Brandon, Feng Zhang, Stuart Schoenherr
Abstract: The present invention relates to a method of providing enhanced resveratrol activity comprising: administering a therapeutically effective amount of 4-acetoxy-resveratrol for the treatment of and preventing physiological and pathophysiological conditions mediated by (1) sirtuins, (2) estrogen and anti-estrogen hormone actions and (3) chemical interventions important for male and female health, aging, anti-aging and age-related disorders.
Type:
Application
Filed:
April 13, 2011
Publication date:
May 16, 2013
Applicant:
BRIGHAM YOUNG UNIVERSITY
Inventors:
Edwin Douglas Lephart, Merritt B. Andrus
Abstract: Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin tolerance were all reserved in the butyrate-treated mice. The body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondria function and biogenesis was observed in the skeletal muscle and brown fat, and Type 1 muscle fiber was enriched in the skeletal muscle. In genetically obese mice, supplementation of butyrate led to an increase in insulin sensitivity and reduction in adiposity. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance.
Abstract: Biodegradable detergent compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable detergent compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.
Type:
Grant
Filed:
September 21, 2011
Date of Patent:
May 7, 2013
Assignee:
DuPont Tate & Lyle Bio Products Company, LLC
Inventors:
Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Raja Hari Poladi, Ann Wehner
Abstract: The invention features compositions and methods that are useful for treating or preventing AAT deficiency and associated conditions. In addition, the invention provides methods for identifying compounds useful for treatment of AAT deficiency and associated conditions.
Type:
Grant
Filed:
July 9, 2009
Date of Patent:
May 7, 2013
Assignee:
University of Florida Research Foundation, Inc.
Abstract: An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue.
Abstract: Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a method for inactivating a virus, a method for dissociating a metal ion from a zinc finger-containing protein, and a method for inhibiting the transmission of a virus.
Type:
Application
Filed:
June 10, 2011
Publication date:
April 18, 2013
Applicants:
Health and Human Services
Inventors:
Daniel Appella, Ettore Appella, John K. Inman, Lisa M. Miller Jenkins, Ryo Hayashi, Deyun Wang
Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and compounds of formula I, and their use in the treatment and/or prevention of diseases and disorders.
Type:
Application
Filed:
March 11, 2011
Publication date:
April 18, 2013
Inventors:
Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, JR.
Abstract: This invention provides a method for treating a cancer caused by cancer stem cells in a subject in need thereof, comprising administering to the subject an effective amount of Antrodia camphorata extracts. The invention also provides a method for treating a cancer caused by cancer stem cells in a subject in need thereof, comprising administering to the subject an effective amount of 4-acetyl-antroquinonol B.
Abstract: The present invention pertains to a method of counteracting a malodor by introducing a malodor counteracting effective amount of a novel 3.2.1-bicyclo-octene or -octane compound represented by formula: wherein R is selected from the group consisting of hydrogen, acetate, carbonate monomethyl ester, and allyloxy; and wherein the broken line represents a single or double bond.
Type:
Grant
Filed:
October 8, 2010
Date of Patent:
April 9, 2013
Assignee:
International Flavors & Fragrances Inc.
Inventors:
Benjamin Amorelli, Johan Gerwin Lodewijk Pluyter, Adam P. Closson
Abstract: Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof are provided. The title compound is shown in formula (I), Y?C14 straight carbon chain. The compound can release 2,6-diisopropylphenol rapidly under the action of enzymes in vivo, which has sedative, hypnotic and/or anesthetic effect. By protecting the hydroxyl group of 2, 6-diisopropylphenol in compound of formula (I), the first-pass metabolic activity of 2, 6-diisopropylphenol is reduced, so that the synthetic compound can be used for sedation, hypnosis, and/or anesthesia.
Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxyiates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
Type:
Application
Filed:
September 14, 2012
Publication date:
March 21, 2013
Applicant:
University of Washington
Inventors:
Tadao Maeda, David SAPERSTEIN, Krzysztof PALCZEWSKI
Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
Type:
Application
Filed:
September 14, 2012
Publication date:
March 21, 2013
Applicant:
University of Washington
Inventors:
Tadao Maeda, David Saperstein, Krzysztof Palczewski
Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
Type:
Application
Filed:
September 14, 2012
Publication date:
March 21, 2013
Applicant:
University of Washington
Inventors:
Tadao Maeda, David Saperstein, Krzysztof Palczewski
Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased.
Abstract: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.
Type:
Application
Filed:
November 9, 2012
Publication date:
March 14, 2013
Applicant:
CATABASIS PHARMACEUTICALS, INC.
Inventors:
Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.
Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.
Abstract: A compound represented by the following formula (I?) wherein X1 is a methylene group, an ethylene group, a trimethylene group or a vinylene group, X2 is a divalent group represented by the following formula A or B, Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X1 is a methylene group, then X2 is not a divalent group represented by the formula A, and when X1 is a vinylene group, then X2 is not a divalent group represented by the formula A. The compound is a stable capsinoid derivative, and is useful as an active ingredient of an external blood circulation enhancer or a cosmetic composition, a pharmaceutical composition, or a food composition.
Abstract: Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating various diseases comprising the administration of an effective amount of at least one compound according to the present disclosure.
Abstract: Active compounds of Formula I are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.
Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.